Masana, LluisLopez Miranda, JoseCiveira, FernandoReinares, LeonardoGuijarro, CarlosPlana, NuriaCuenca, RafaelSanchez, DemetrioHernandez, Jose LuisAndres, RaimundoBlanco, AgustinVillamayor, Santiago2023-02-082023-02-082020-02-24Masana L, López Miranda J, Civeira F, Reinares L, Guijarro C, Plana N, Cuenca R, et al. Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU). Clin Investig Arterioscler. 2020 Sep-Oct;32(5):183-192. English, Spanish.http://hdl.handle.net/10668/15404To describe the clinical characteristics, the reasons for initiating therapy, and the effects of treatment in the initial phase of evolocumab availability in lipid/internal medicine units in Spain. Retrospective, observational study, based on the medical records of consecutive patients initiating treatment with evolocumab (from February 2016 to July 2017) in 20 internal medicine units in Spain. A review was made of the demographic and clinical characteristics of the patients, the lipid lowering treatment, and the evolution of the lipid profiles between 12weeks pre-initiation and 12±4weeks post-initiation of evolocumab. A total of 136 patients were analysed, of whom 64.0% were men, and the mean age (standard deviation, SD) was 56.6 (11.5) years. The large majority (75%) had familial hypercholesterolaemia (4 homozygous), and 51.0% of them had suffered at least one cardiovascular event. Atherosclerotic cardiovascular disease (ASCVD) was present in 61% of all patients. At initiation of evolocumab, 61.0% of the patients were taking high-intensity statins, and 60.3% were receiving ezetimibe. The mean (and SD) of LDL-C levels at initiation of evolocumab was 169.1 (56.6) mg/dL. The LDL-C was greater than 160mg/dL in 46.4% of patients, and ≥190mg/dL in 26.5%. During the observation period, evolocumab produced significant reductions in LDL-C of 55.7% (P In the lipid/internal medicine units, evolocumab was mainly prescribed in patients with familial hypercholesterolaemia, with or without ASCVD. The initial use of evolocumab was in accordance with the guidelines of the Spanish Society of Arteriosclerosis (SEA) of 2016, with LDL-C levels being well above the recommended thresholds for treatment initiation. Evolocumab treatment in clinical practice reduced LDL-C levels by about 55%, a similar reduction to that reported in clinical trials. Most patients achieved LDL-C goals.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Arteriosclerotic cardiovascular diseaseEnfermedad cardiovascular arterioscleróticaEvolocumabFamilial hypercholesterolaemiaHipercolesterolemia familiarLDL-CLipid unit/internal medicineUnidades de lípidos/medicina internacLDLAgedAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsAtherosclerosisCholesterol, LDLEzetimibeFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipoproteinemia Type IIMaleMiddle AgedRetrospective StudiesSpainresearch article32317124open accessAnticolesterolemiantesAnticuerpos monoclonalesAterosclerosisEzetimibaHiperlipoproteinemia Tipo IIHidroximetilglutaril-CoAReductasas10.1016/j.arteri.2020.02.0031578-1879https://doi.org/10.1016/j.arteri.2020.02.003